Articles tagged with Colorectal Cancer
Researchers found that long-term yogurt intake was associated with lower rates of proximal colon cancer positive for Bifidobacterium, a bacterial species found in yogurt. The study showed that higher yogurt consumption over time may protect against colorectal cancer through changes in the gut microbiome.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
Researchers discover Artemisia herba-alba extract stops cancer cell growth and causes them to die, with potential as a complementary treatment. The study highlights the plant's selective cytotoxicity against CRC cell lines, offering a promising natural ingredient for new cancer treatments.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
Researchers identified distinct molecular features of early onset colorectal cancer in racial and ethnic minorities, including widespread changes in DNA methylation and metabolic gene expression. These findings suggest that environmental risk factors such as diet and stress may contribute to the disparities in incidence and mortality a...
A team of researchers at Johns Hopkins Medicine has developed a biomarker algorithm that can detect Barrett’s esophagus and esophageal cancer using a noninvasive method. The algorithm uses methylation patterns in genes to identify biomarkers, achieving an AUC of nearly 0.97 in distinguishing healthy tissue from esophageal cancer.
Researchers at University of Birmingham have discovered three new protein biomarkers TFF3, LCN2, and CEACAM5 that show strong predictive potential for colorectal cancer. These biomarkers are linked to cell adhesion and inflammation, processes closely associated with cancer development.
Researchers at Johns Hopkins Medicine identified a new epigenetic approach to target colorectal cancer, using a mouse protein that disrupts cancer-causing chemical changes in genes. The study found that the protein, STELLA, can be used to develop a drug strategy to treat solid tumors.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
A recent study published in The Lancet Oncology reveals a global surge in early-onset colorectal cancer cases, with 27 countries experiencing significant increases in young adults. The research highlights the need for innovative prevention strategies tailored to younger generations and local resources worldwide.
A new study suggests that a person's biological age can predict their risk of developing colon polyps and early colorectal cancer. Accelerated aging, which is higher than chronological age, may be linked to a greater risk of developing the disease, highlighting the importance of early screening.
Researchers at USF and TGH Cancer Institute found a potential link between the Western diet and chronic inflammation that drives tumor growth. Chronic inflammation fueled by poor dietary choices plays a vital role in colorectal cancer growth and progression.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
Researchers identify two strains of bacteria producing colibactin as a potential link to colorectal, bladder, and prostate cancers. Targeting these strains with vaccines or probiotics could reduce cancer risk and infection burden.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Researchers urge people to improve their eating habits to reduce the risk of bowel cancer, citing evidence that high-fibre foods promote healthy gut bacteria. Studies found a link between poor diet choices and digestive cancers, highlighting the importance of diets rich in whole grains, vegetables, fruits, and legumes.
The updated ASTRO guideline recommends personalized treatment approaches for patients with locally advanced rectal cancer, including non-surgical alternatives and intensified treatment regimens. The guideline aims to improve outcomes while preserving quality of life.
A new study shows that mailing at-home fecal immunochemical testing kits and providing coordinated follow-up led to a tripling of screening completion rates compared to usual care. The intervention increased screening rates by 30% within six months and 34.6% by 12 months.
A cohort study reveals racial and ethnic variations in early-onset colorectal cancer mortality, with Native Hawaiian or Other Pacific Islander and non-Hispanic Black individuals facing the highest burden. Social determinants of health play a significant role in explaining these disparities.
Researchers sequenced tissue and plasma samples from patients with conventional CRAs to identify genetic alterations. They found that a small proportion of samples successfully detected tissue-origin variants within matched cfDNA. The study also explored the genomic characteristics and progression of cancer from CRA to CRC-I, highlight...
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Emerging endoscopic technologies, such as wide-field and microscopic-field techniques, enhance CRC screening. AI-driven tools improve polyp detection rates and reduce biopsy rates, while robotic colonoscopy offers procedural precision and patient comfort.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
A recent study demonstrates that stool DNA testing is highly sensitive and specific for detecting colorectal cancer among Thai individuals, with a sensitivity of 91.5% and specificity of 90.3%. The test targets methylation statuses of three genes and may provide a viable non-invasive alternative to colonoscopy.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
Researchers create genetic barcoding approach to record cellular events and clonality in vivo, revealing that colorectal cancer originates from multiple healthy cells. This work provides a new understanding of the transition from polyclonal to monoclonal composition in advanced stages.
Researchers identified three long noncoding RNAs associated with worse outcomes in colorectal cancer patients, potentially serving as prognostic markers. The study's findings could enable doctors to separate high-risk patients from those at low risk of disease recurrence, leading to more effective treatment strategies.
A recent study by Stanford Medicine suggests that new blood-based colon cancer screening tests are effective for people who shun traditional methods. However, if too many switch to the new tests, colorectal cancer death rates may rise due to reduced detection of early cancers and precancerous polyps.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers developed grain-sized soft robots that can transport up to four different drugs, release them in reprogrammable orders and doses, and navigate complex environments inside the human body. The robots' precision functions have the potential to significantly improve therapeutic outcomes while minimizing side effects.
UTEP researchers developed a portable device that can detect colorectal and prostate cancer quickly and accurately, reducing the need for costly instruments. The device is low-cost, sensitive, and analyzes samples in just an hour.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
A new study reveals that high levels of dietary iron from red meat reactivates telomerase, driving colorectal cancer progression. A promising small molecule, SP2509, blocks this reaction, offering hope for targeted therapies in Singapore and globally.
A systematic review of randomized clinical trials found that AI-assisted colonoscopies increased overall detection of colonic polyps and adenomas, with a small increase in procedure time. Researchers also found no clear differences in benefit for detecting adenomas across different AI systems.
A Kaiser Permanente study found that close to 39% of adults aged 45-49 returned their FIT kit, compared to nearly 38% of adults aged 50. The study suggests that adults in this age group have a similar colorectal cancer risk as those aged 50.
Younger adults diagnosed with colorectal cancer have later-stage disease with more aggressive types of tumors. Obesity, family history, inflammatory bowel disease, and symptoms are strongly associated factors. These findings highlight disparities in colon cancer incidence among younger adults, particularly non-Hispanic Black patients.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
A new study reveals how chronic stress disrupts the balance of gut microbiota to speed up the progression of colorectal cancer. The research identified a particular bacterial species as a potential therapeutic target, specifically Lactobacillus genus, which is essential for a healthy immune response against cancer.
Researchers developed a machine learning model to predict mesenteric lymph node metastasis preoperatively in colorectal cancer patients. The XGB-based model achieved high accuracy, identifying key predictors such as perineural invasion and hematocrit levels.
A new study aims to increase follow-up care for patients who receive abnormal stool-based fecal immunochemical tests, focusing on improving coordination between primary and specialty clinics. The goal is to improve colorectal cancer screening processes in underserved populations, increasing survival and reducing mortality.
A large proportion of gene variants previously classified as 'variants of uncertain significance' (VUS) have been reclassified as benign, according to a study published in the American Journal of Human Genetics. This reduces the total number of VUS by 37%, providing relief for carriers worldwide.
Researchers found that humorous comic strip cartoons increased likelihood of agreeing to take a quiz on personal risk for colon cancer. Exposing people to funny content reduced information avoidance, making them more likely to choose to watch a video about colorectal cancer prevention.
A double-blind randomized phase 3 clinical trial found no additional benefits from high-dose vitamin D3 when added to standard chemotherapy for patients with untreated metastatic colorectal cancer. However, a potential benefit was observed for left-sided disease patients.
A single-center cohort study identified substantial overall survival disparity among racial and ethnic groups, with socioeconomic status contributing less than a third of the disparity. Tumor molecular features also played a significant role in the disparities found in colorectal cancer survival.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
Patients with early-onset colorectal cancer living in rural areas had lower 5-year survival rates compared to urban counterparts. Persistent poverty in these areas may compound this association, affecting overall survival outcomes.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.